Serina Therapeutics, Inc. (SER) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 16, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Serina Therapeutics, Inc. (SER), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Serina Therapeutics, Inc., analysts forecast revenue falling from $130,000 in 2025 to $0 in 2030; the average estimate for 2030 earnings per share is −$1.22; 2 analysts contribute to these figures. These are forecasts published by analysts, not results.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Serina Therapeutics, Inc. (SER) forecast — frequently asked questions
What are analysts forecasting for Serina Therapeutics, Inc.'s earnings?
The average analyst estimate for Serina Therapeutics, Inc. (SER) earnings per share in 2030 is -1.22, with individual estimates between -1.22 and -1.22.
How much revenue is Serina Therapeutics, Inc. expected to make?
Analysts forecast Serina Therapeutics, Inc. (SER) revenue of $0 in 2030, based on 1 published estimates.
How many analysts cover SER?
2 analysts contribute estimates for Serina Therapeutics, Inc. (SER). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.